A high vancomycin trough means the lowest concentration of the drug in the blood, measured just before the next dose, has risen above the target range. The response depends on how high it is: levels between 20 and 25 mcg/mL typically call for a dose reduction, while levels above 25 mcg/mL usually require holding the next dose entirely and rechecking the level before restarting. In either case, kidney function needs immediate attention because vancomycin is cleared almost entirely by the kidneys, and a rising trough is often the first signal that something has changed.
What Counts as a High Trough
For serious MRSA infections, the previously recommended target trough was 15 to 20 mcg/mL. For less invasive infections like cellulitis, troughs of 5 to 10 mcg/mL were associated with low rates of kidney injury. Any trough above the intended target range is considered elevated, but the real concern starts above 20 mcg/mL. At that level, acute kidney injury risk climbs significantly. Troughs above 25 mcg/mL are clearly supratherapeutic and require more aggressive intervention.
It’s worth noting that current guidelines have shifted away from trough-only monitoring for serious MRSA infections. The preferred approach now uses a measure called AUC/MIC, which captures the drug’s total exposure over 24 hours rather than relying on a single low-point reading. The recommended AUC/MIC target is 400 to 600, and keeping the AUC below 800 minimizes kidney damage. A pharmacist or clinical team using AUC-based software may interpret your trough result differently than older trough-only protocols would.
First Steps When the Trough Is Elevated
The immediate response follows a fairly straightforward pattern based on how far above target the level has climbed:
- Trough 20 to 25 mcg/mL: Reduce the dose while keeping the same dosing interval. The size of the reduction depends on how far above target the level is, but the goal is to bring the next trough into the desired range without interrupting therapy.
- Trough above 25 mcg/mL: Hold the dose entirely. A common protocol is to cut the dose by 50% once therapy resumes. For example, a patient on 1000 mg every 12 hours with a trough of 29 mcg/mL would restart at 500 mg every 12 hours.
When a dose is held, the level should be rechecked before restarting. One widely used guideline recommends holding for 24 hours, then redrawing the level and restarting at a reduced dose only once the trough drops below 20 mcg/mL.
Check Kidney Function Right Away
Vancomycin is cleared through the kidneys. When the dose hasn’t changed but the trough has risen, that’s a reliable early indicator that kidney filtration has slowed. Serum creatinine should be checked alongside the trough result, and if it’s climbing, the high trough may be both a consequence of reduced kidney function and a contributor to further kidney damage.
The risk factors that compound kidney injury alongside a high trough include pre-existing impaired kidney function (especially filtration rates below 30 mL/min), use of certain other antibiotics or diuretics at the same time, and being in an intensive care setting. Patients receiving vancomycin for longer than seven days at high trough targets are at particular risk, with some developing nephrotoxicity at trough levels ranging from 23 to over 40 mcg/mL.
Even troughs in the 15 to 20 mcg/mL range carry a meaningfully higher risk of acute kidney injury compared to troughs of 10 to 15 mcg/mL. One large analysis found the odds of kidney injury were about 63% higher at troughs of 15 to 20 compared to 10 to 15. This is one reason current guidelines favor AUC-guided dosing, which can often achieve the same bacterial killing with lower trough levels.
Rule Out a False High Reading
Before making dose changes, it’s important to confirm the trough was drawn correctly. A surprisingly common source of falsely elevated readings is improper timing. The trough should be drawn just before the next scheduled dose, ideally within 30 minutes of administration time, and only after steady state has been reached (typically before the fourth dose in patients with normal kidney function).
Troughs drawn more than two hours before the next scheduled dose can overestimate the true trough concentration because the drug is still in its distribution phase. In some cases, documentation errors make it appear the sample was drawn after a dose when it actually was not. If the level seems unexpectedly high and the clinical picture doesn’t match (stable creatinine, no signs of toxicity), verifying the draw time is a reasonable first step before adjusting therapy.
Hearing Loss Is Less Predictable
Kidney injury gets the most attention, but some patients and clinicians also worry about hearing damage. The relationship between vancomycin trough levels and hearing loss is less clear-cut than the kidney connection. Research has shown that serum vancomycin levels do not reliably correlate with ototoxicity, and studies comparing patients with and without hearing changes have found no significant differences in trough levels between the two groups.
The risk appears to increase when vancomycin is given alongside other medications known to affect hearing, such as certain diuretics. Whether these drugs have an additive effect with vancomycin on hearing remains uncertain, but it’s a consideration when a patient is on multiple medications and trough levels are running high.
After the Dose Adjustment
Once the dose has been reduced or restarted, a new trough should be drawn to confirm the level has come into range. The standard timing is before the third, fourth, or fifth dose after the change. If kidney function is severely impaired (filtration below 10 mL/min), rechecking within 48 hours is appropriate because drug clearance is so slow that accumulation can happen quickly.
Ongoing monitoring should track both vancomycin levels and creatinine together. A rising creatinine even with an in-range trough still signals trouble, and a stable creatinine with a trending-up trough suggests clearance is shifting. The two values are most useful when interpreted as a pair. For serious MRSA infections, transitioning to AUC-guided monitoring with clinical software, when available, provides a more precise picture of drug exposure than any single trough reading can offer.